MAR 30, 2016 8:43 AM PDT

Recruiting Plant Peptides to Treat Multiple Sclerosis

WRITTEN BY: Kara Marker
Multiple Sclerosis (MS) is an autoimmune disease characterized by chronic inflammation, a result from an overexcited, misdirected immune response. A synthesized plant polypeptide called cyclotide is found in a variety of common plants, and it has the capability to reduce MS-related inflammation to the point where the disease can be curbed at a very early stage.
 

 MS is currently incurable, with available treatments to reduce the rate of progression including harsh side effects. The overactive inflammatory response causing MS stems from the destruction of myelin sheaths, the components of the nervous system that insulate nerve fibers. The current study indicating the future use of cyclotides as a more effective treatment was completed at the Medical University of Vienna and recently published in the journal PNAS.
 
“This could slow down the course of the disease in general,” said Christian Gruber, PhD, Chief Researcher at the Center for Physiology and Pharmacology at the university, said about the clinical sue of cyclotides.
 
In an animal model of MS, the research time orally administrated cyclotides and saw reduced symptoms of MS to the point where the most successful case showed no further progression of MS clinical signs. These preliminary studies mean that as soon as people start to show functional neurological problems that are characteristic of MS and receive a confirmative diagnose of MS via magnetic resonance imaging (MRI), the drug could be administered to prevent any further progression of the disease.
 
Cyclotides can be isolated from common plants like coffee, cucurbits, grass, and nightshade. It is highly advantageous that the drug develop from these macrocyclic peptides can be taken orally; most current treatments have to be administered intravenously.
 
By suppressing interleukin-2, an inflammatory cytokine that promotes the division of T lymphocytes, cyclotides reduce inflammation in patients with MS. When a reasonable cause instigates interleukin-2 production and activation of T lymphocytes, this is a protective pathway for the body. However, cases of MS are characterized by an inappropriate release of interleukin-2, leading to unnecessary inflammation, so suppressing the cytokine will successful reduce the severity of MS.
 
Additionally, cyclotide-based drugs have the potential to treat other autoimmune diseases characterized by an “overactive, misdirected immune response.”
 
Researchers from the Medical University of Vienna have authorized further development to be carried out at a pharmaceutical company called Cyxone.  A clinical trial testing the drug could begin as early as the end of 2018. More than 2.5 million people worldwide are affected by MS, and cyclotide-based drugs could be the first medication to truly make a difference in their lives.
 
 
Source:  Medical University of Vienna
 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
OCT 01, 2020
Clinical & Molecular DX
Presenting the World's Smallest Ultrasound Detector
OCT 01, 2020
Presenting the World's Smallest Ultrasound Detector
It’s smaller than a human cell, but the diminutive size of the newly-developed ultrasound detector is by no means ...
OCT 02, 2020
Immunology
Stop the Clot: A New Antibody Treatment for Thrombosis
OCT 02, 2020
Stop the Clot: A New Antibody Treatment for Thrombosis
Blood clotting helps stem the bleeding from a wound, suppressing blood loss and stopping pathogenic microorganisms from ...
OCT 05, 2020
Immunology
Can't Shed Those Extra Pounds? An Inflammatory Gene Could Be to Blame.
OCT 05, 2020
Can't Shed Those Extra Pounds? An Inflammatory Gene Could Be to Blame.
  Australian scientists have zeroed in on a gene linked to an increased obesity risk: a regulator of inflammation c ...
OCT 12, 2020
Drug Discovery & Development
In vitro glycoengineering - Suitability for BioPharma manufacturing
OCT 12, 2020
In vitro glycoengineering - Suitability for BioPharma manufacturing
Introduction The importance of Fc glycosylation of monoclonal antibodies (mAbs) with regard to biological activity is wi ...
OCT 15, 2020
Health & Medicine
An Estimated 38 Million People were Exposed to Polluted Wildfire Smoke
OCT 15, 2020
An Estimated 38 Million People were Exposed to Polluted Wildfire Smoke
As wildfires continue to burn record-breaking acreages along the west coast of the United States and inland regions, hos ...
OCT 23, 2020
Clinical & Molecular DX
Follow Your Heart: A Genetic Predictor of Cardiovascular Disease
OCT 23, 2020
Follow Your Heart: A Genetic Predictor of Cardiovascular Disease
Cardiovascular disease is the leading cause of death globally, resulting in the loss of nearly 18 million lives each yea ...
Loading Comments...